Fibromuscular dysplasia secondary prevention: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| (One intermediate revision by the same user not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Fibromuscular dysplasia}} | {{Fibromuscular dysplasia}} | ||
{{CMG}}; {{AE}} | {{CMG}}; {{AE}}{{M.B}} | ||
==Overview== | ==Overview== | ||
There are no established measures for the secondary prevention of | There are no established measures for the secondary prevention of FMD. | ||
==Secondary Prevention== | ==Secondary Prevention== | ||
There are no established measures for the secondary prevention of FMD. | |||
==References== | ==References== | ||
Latest revision as of 02:43, 2 August 2018
|
Fibromuscular dysplasia Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
ASA/ACCF/AHA Guideline Recommendations |
|
Management of Patients With Fibromuscular Dysplasia of the Extracranial Carotid Arteries |
|
Case Studies |
|
Fibromuscular dysplasia secondary prevention On the Web |
|
American Roentgen Ray Society Images of Fibromuscular dysplasia secondary prevention |
|
Risk calculators and risk factors for Fibromuscular dysplasia secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mohsen Basiri M.D.
Overview
There are no established measures for the secondary prevention of FMD.
Secondary Prevention
There are no established measures for the secondary prevention of FMD.